COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05925127

Novavax Customer Service Center

Not reported

2023-06-29

Not recruiting

RCT

Randomized

Crossover

Blind label

multi-center

Prevention

inclusion criteria: adults ≥ 50 years of age at screening. willing and able to give informed consent prior to study enrollment and to comply with study procedures. female participants of childbearing potential (defined as any participant who has experienced menarche and who is not surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea ≥ 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through the end of the study or agree to consistently use a medically acceptable method of contraception listed below from ≥ 28 days prior to enrollment and through the end of the study. is medically stable, as determined by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). vital signs must be within medically acceptable ranges prior to the initial study vaccination. agrees to not participate in any other sars-cov-2 prevention or treatment trials for the duration of the study. have previously received ≥ 3 doses of a covid-19 prototype or bivalent licensed mrnavaccine with the last dose having been given ≥ 90 days previously prior to first study booster.

received covid-19 vaccines other than a covid-19 prototype or bivalent licensed mrna vaccine in the past, inclusive of clinical trial covid-19 vaccines. participation in research involving receipt of investigational products (drug/biologic/device) within 90 days prior to study vaccination. received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine within 30 days prior to first study vaccination. any known allergies to products contained in the investigational product. 5. any history of anaphylaxis to any prior vaccine. 6. autoimmune or immunodeficiency disease/condition (iatrogenic or congenital) requiring ongoing immunomodulatory therapy. 7. chronic administration (defined as > 14 continuous days) of immunosuppressant, systemic glucocorticoids, or other immune-modifying drugs within 90 days prior to study vaccination. note: an immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. the use of topical or intranasal glucocorticoids is permitted. topical tacrolimus and ocular cyclosporin are permitted. use of inhaled glucocorticoids is prohibited. 8. received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to study vaccination, except for rabies immunoglobulin which may be given if medically indicated. 9. active cancer (malignancy) on therapy within 3 years prior to study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo maligna and uterine cervical carcinoma in situ without evidence of disease, at the discretion of the investigator). 10. participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the end of study. 11. suspected or known history of alcohol abuse or drug addiction within 2 years prior to the study vaccine dose that, in the opinion of the investigator, might interfere with protocol compliance. 12. any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions likely to impair the quality of safety reporting). 13. study team member or immediate family member of any study team member (inclusive of sponsor, contract research organization (cro), and study site personnel involved in the conduct or planning of the study). 14. participants with a history of myocarditis or pericarditis.

7

Novavax

18

50

United States

Healthy volunteers

N/A

1980

Immunogenicity index-Neutralizing antibody expressed as geometric mean titer ratio[GMTR ]against the Omicron subvariant XBB.1.5;Immunogenicity index-Neutralizing antibody expressed as seroresponse rates (SRRs)against the Omicron subvariant XBB.1.5

None

Phase 2/Phase 3

[{"arm_notes": "nan", "treatment_id": 2696, "treatment_name": "Mrna vaccine bivalent", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5\u03bcg of antigen with 50 \u03bcg of Matrix-M adjuvant", "treatment_id": 918, "treatment_name": "Nvx-cov2373", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u03bcg of antigen with 50\u03bcg of Matrix-M adjuvant", "treatment_id": 2758, "treatment_name": "Nvx-cov2601", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "5 \u03bcg of antigen with 75 \u03bcg of Matrix-M adjuvant", "treatment_id": 2758, "treatment_name": "Nvx-cov2601", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "35 \u03bcg of each antigen with a 75 \u03bcg of Matrix-M adjuvant", "treatment_id": 2758, "treatment_name": "Nvx-cov2601", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "35 \u03bcg of antigen with 50 \u03bcg of Matrix-M adjuvant", "treatment_id": 2758, "treatment_name": "Nvx-cov2601", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "50 \u03bcg of each antigen with a 100 \u03bcg of Matrix-M adjuvant", "treatment_id": 2758, "treatment_name": "Nvx-cov2601", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]